Next-generation probiotics (NGPs) have been widely investigated as a treatment modality for gastrointestinal disorders. With extensive expertise in the human probiotic field, Creative Biolabs is committed to deepening our understanding of the role of microbiota in human health aided by our next-generation sequencing and analytic tools, experimental technologies, and animal models. We have explored a live biotherapeutics discovery platform for NGPs development, pre-clinical studies, and cGMP manufacturing to address different demands for pre-clinical, clinical, and commercial applications.
The human microbiota is a very complex ecologic system that is necessary for health, but also has the potential to contribute to the development of diseases. Perturbations of bacterial microflora in the intestinal epithelial barrier are associated with a number of gastrointestinal (GI) conditions, the best studied of which are inflammatory bowel diseases (IBD), Clostridium difficile infection (CDI), ulcerative colitis (UC), and pouchitis. To alter the intestinal microflora, there are four general methods: administration of antibiotics, administration of antibiotics, prebiotics (dietary components that promote the growth and metabolic activity of beneficial bacteria), probiotics (live, beneficial bacteria), or fecal microbial transplant (FMT).
There is a complex relationship between GI diseases, health, the immune system, and alterations in the microbiota, therefore, the mechanisms of action of NGPs are comparatively complex and likely differ by bacteria species.
Fig.2 Known mechanisms distributed among various probiotic strains. (Sanders, 2019)
Strains of bacteria that have been widely genetically engineered to prevent and treat GI diseases (given alone or in combination) are under constant development. There is a range of NGP strains have been investigated, mainly including the following species:
With industry-leading expertise and state-of-the-art single-use equipment, Creative Biolabs provides flexible solutions to choose, either stand-alone service or integrated project is both welcome to meet every specific demand. We aspire to become a leading, fully integrated biopharmaceutical company focused on the discovery, analysis, manufacturing, and commercialization of next-generation probiotics.
Supplementation of the gastrointestinal microbiota with appropriate NGPs is now widely used as an alternative therapeutic approach for GI disorders. Based on our expertise in microbiota and microbiome science, Creative Biolabs provides comprehensive services for the development of NGPs from carefully selected strains. Separate services or integrated end-to-end solutions are all welcomed. If you are interested in our services, please feel free to contact us.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.